<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739202</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0153</org_study_id>
    <secondary_id>2020-000297-17</secondary_id>
    <nct_id>NCT04739202</nct_id>
  </id_info>
  <brief_title>Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)</brief_title>
  <acronym>IMMUNOGAST</acronym>
  <official_title>An Umbrella Phase 2 Trial to Assess Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent Advanced/Metastatic GASTric Adenocarcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with advanced/metastatic gastric adenocarcinomas in progression after a first&#xD;
      line chemotherapy comprising platinum and fluoropyrimidine, the reported second line&#xD;
      treatments are : 1) paclitaxel combined with ramucirumab (overall response rate (ORR) = 25%;&#xD;
      median progression free survival (PFS) = 2.9 months; median overall survival (OS)= 5.9&#xD;
      months), or paclitaxel alone (ORR = 14%, median PFS = 2.9 months; median OS= 5.9 months); 2)&#xD;
      docetaxel (ORR = 7%, median OS = 5.2 months) or 3) irinotecan (ORR = 0%, median OS= 4.0&#xD;
      months).&#xD;
&#xD;
      These numbers demonstrate the poor prognosis of this disease, and the unmet medical need for&#xD;
      innovative therapeutic strategies.&#xD;
&#xD;
      Cancer Genome Atlas (TCGA) mapped a genomic landscape of gastric adenocarcinomas, and&#xD;
      identified 4 sub-types:&#xD;
&#xD;
        -  Tumor positive for Epstein-Barr virus (EBV) (8%), which display recurrent PIK3CA&#xD;
           mutations, extreme DNA hypermethylation, and amplification of JAK2, ErbB2, PD-L1 and&#xD;
           PD-L2;&#xD;
&#xD;
        -  Microsatellite instable tumors (MSI-high) (22%), which show elevated mutation rates,&#xD;
           including mutations of genes encoding targetable oncogenic signaling proteins (PIK3CA,&#xD;
           ErbB2, ErbB3, and EGFR);&#xD;
&#xD;
        -  Genomically stable tumors (20%), which are enriched for the diffuse histological variant&#xD;
           and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins;&#xD;
&#xD;
        -  Tumors with chromosomal instability (50%), which show marked aneuploidy and focal&#xD;
           amplification of receptor tyrosine kinases and VEGFA.&#xD;
&#xD;
      Most of diffuse-type gastric adenocarcinomas were classified in genomically stable tumors.&#xD;
      This subgroup of cancers, accounting for about 20 to 30% of gastric adenocarcinomas, is&#xD;
      associated with particularly poor prognosis and resistance to chemotherapy. A proteomic&#xD;
      landscape of diffuse-type gastric adenocarcinomas was recently reported.&#xD;
&#xD;
      Pembrolizumab, an anti-PDL1 drug granted with an accelerated approval by FDA in September&#xD;
      2017, exhibited promising activity in gastric adenocarcinoma patients previously treated with&#xD;
      1 or 2 lines of chemotherapy (ORR=11.6%, median PFS = 2.0 months, median OS= 5.6 months),&#xD;
      especially in those with PDL1 positive tumors (ORR=22.7%). The tumor response was&#xD;
      particularly high in patients with MSI-high tumor (ORR=57.1%). However the preliminary&#xD;
      outcomes of the phase III KEYNOTE-061 trial (NCT02370498) recently released in the press&#xD;
      suggest that pembrolizumab was not superior to paclitaxel in 592 patients with advanced&#xD;
      gastric or gastroesophageal junction adenocarcinoma whose disease progressed after first-line&#xD;
      treatment with platinum and fluoropyrimidine doublet therapy (the hazard ratio (HR) for OS&#xD;
      was 0.82 (95% confidence interval = 0.66-1.03; one sided P = .042)&#xD;
      (http://www.ascopost.com/News/58377).&#xD;
&#xD;
      These outcomes suggest that, although being very promising, immunotherapy should be combined&#xD;
      to other agents for being fully effective in gastric adenocarcinomas patients.&#xD;
&#xD;
      We propose a strategy based on molecular features to select the drugs that will be associated&#xD;
      with atezolizumab, an anti-PDL1 drug, in patients with pre-treated advanced gastric&#xD;
      adenocarcinomas:&#xD;
&#xD;
        -  Patients with tumors positive for EBV or microsatellite instable tumors (30%) will be&#xD;
           treated with atezolizumab and ipatasertib.&#xD;
&#xD;
        -  Patients with genomically stable tumors (20%) will be treated with atezolizumab combined&#xD;
           with bevacizumab.&#xD;
&#xD;
        -  Patients with tumors with chromosomal instability (50%) will be treated with&#xD;
           atezolizumab combined with bevacizumab.&#xD;
&#xD;
      Expected outcomes:&#xD;
&#xD;
      IMMUNOGAST trial will provide data about the clinical feasibility of biomolecular&#xD;
      characterization of gastric adenocarcinomas for routine treatment adjustment. Moreover it&#xD;
      should generate information about the relevance of adjusting combined immunotherapies based&#xD;
      on molecular subtypes, in terms of clinical efficacy. Finally, translational research project&#xD;
      outcomes should provide important data about relationships between efficacy and tumor immune&#xD;
      gene spatial expression, along with tumor and circulating mutational burden. These outcomes&#xD;
      may help identify the best candidates for tested combinations in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">October 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 26, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Through the expected duration of the treatment, an average of 27 weeks and a maximum of 2 years (estimated)</time_frame>
    <description>Objective response rate, using iRECIST, defined as the percentage of patients experiencing a complete response or a partial response, as their best tumor responses during the whole treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of inclusion (Day -28 to Day 0) to the date of death or to the end of the study or in a complementary study (to collect vital status and date of death, every 3 months for 5 years for patients alive at the end of the study</time_frame>
    <description>The overall survival (OS) will be measured from the date of inclusion to the date of death or to the end of the study or in a complementary study (to collect vital status and date of death, every 3 months for 5 years for patients alive at the end of the study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From the date of inclusion (Day -28 to Day 0) to the date of disease progression, or death or to the end of the study up to 52.5 months</time_frame>
    <description>The progression-free survival (PFS) will be evaluated according to iRECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, treatment-related adverse events</measure>
    <time_frame>100 days after the last experimental treatment</time_frame>
    <description>Treatment-related adverse events are defined as the nature, number and grade of adverse events observed throughout the study and assessed using NCI-CTCAE v.5.0 criteria.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Metastatic Gastric Cancer</condition>
  <condition>Metastatic Adenocarcinoma</condition>
  <condition>Advanced Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>Patients with tumors positive for EBV or microsatellite instable tumors (group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab IV (1200 mg every 3 weeks) + Ipatasertib tablet (400 mg a day continuously).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with genomically stable tumors (group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with tumors with chromosomal instability (group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab IV (1200 mg every 3 weeks) + Bevacizumab IV (15 mg/kg every 3 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab + Ipatasertib</intervention_name>
    <description>Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Patients with tumors positive for EBV or microsatellite instable tumors (group 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab + Bevacizumab</intervention_name>
    <description>Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Patients with genomically stable tumors (group 2)</arm_group_label>
    <arm_group_label>Patients with tumors with chromosomal instability (group 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically and/or cytologically documented recurrent advanced/metastatic gastric&#xD;
             or gastroesophageal junction adenocarcinomas* previously treated with a platinum and&#xD;
             fluoropyrimidine-based regimen.&#xD;
&#xD;
             * The gastric or gastroesophageal junction adenocarcinomas that overexpress HER2&#xD;
             should have previously been treated with trastuzumab, except in the case of&#xD;
             contraindication.&#xD;
&#xD;
          -  Patients older than 18 years&#xD;
&#xD;
          -  Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
          -  Patients must have documented disease progression&#xD;
&#xD;
          -  Patients who have measurable disease according to Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) v1.1&#xD;
&#xD;
          -  Accessible tumor lesion (primitive lesion or metastasis) for trial dedicated tumor&#xD;
             biopsy.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (echo) or multigated&#xD;
             acquisition (MUGA) scan within 28 days before day 1 of treatment.&#xD;
&#xD;
          -  Child-Pugh class A&#xD;
&#xD;
          -  Patients must have normal organ and marrow function:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/μL, platelets ≥ 100,000/μL, hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 ULN except subject with documented Gilbert's syndrome,&#xD;
                  AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN, Serum alkaline phosphatase ≤ 2.5 x&#xD;
                  ULN. Patients with bone metastases: alkaline phosphatase ≤ 5 x ULN.&#xD;
&#xD;
               -  Albumin &gt; 2.5 mg/dL.&#xD;
&#xD;
               -  Glomerular filtration rate ≥ 60 mL/min as determined by the CKD-EPI equation (or&#xD;
                  reference methodology such as Iohexol or isotopic technic).&#xD;
&#xD;
               -  Urine dipstick for proteinuria &lt; 2+. If urine dipstick is ≥ 2+, 24-hour urine&#xD;
                  must demonstrate &lt; 1 g of protein in 24 hours.&#xD;
&#xD;
               -  Normal blood pressure or adequately treated and controlled hypertension (systolic&#xD;
                  BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg).&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative serum pregnancy test&#xD;
             within 8 days of initiating protocol therapy.&#xD;
&#xD;
          -  Female patients of childbearing potential must agree to use contraceptive methods with&#xD;
             a low failure rate (&lt; 1% per year) during the treatment period and for 6 months after&#xD;
             the last dose of study drugs.&#xD;
&#xD;
          -  Male patients of childbearing potential must agree to use contraceptive methods with a&#xD;
             low failure rate during the treatment period and for 6 months after the last dose of&#xD;
             study drugs.&#xD;
&#xD;
          -  Patient is capable of understanding and complying with the protocol and has signed the&#xD;
             informed consent document.&#xD;
&#xD;
          -  Patients affiliated to a social insurance regime.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Residual toxicity from previous treatment grade ≥1, except for alopecia or peripheral&#xD;
             neuropathy grade ≤ 2&#xD;
&#xD;
          -  Radiotherapy within 28 days before inclusion, except for palliative radiotherapy if&#xD;
             patients recovered from all side effects&#xD;
&#xD;
          -  Congenital risk of bleeding, or acquired coagulopathy, or curative anti-coagulant&#xD;
             therapies (except for low molecular weight heparin).&#xD;
&#xD;
          -  Active digestive bleeding within 3 months before inclusion&#xD;
&#xD;
          -  Patients pretreated with one of the experimental drugs, other immune checkpoint&#xD;
             inhibitor anti-cancer drugs (anti-PD1, anti-PDL1, anti-CTLA4, …), or with ramucirumab.&#xD;
&#xD;
          -  Uncontrolled high cholesterol or triglyceride grade ≥ 2&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, including, but not limited to, ongoing or active&#xD;
             infection, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac&#xD;
             arrhythmia, congestive heart failure-New York Heart Association Class III or IV,&#xD;
             active ischemic heart disease, myocardial infarction within the previous six months,&#xD;
             uncontrolled diabetes mellitus, gastric or duodenal ulceration diagnosed within the&#xD;
             previous 6 months, chronic liver or renal disease, or severe malnutrition.&#xD;
&#xD;
          -  Current peripheral neuropathy of Grade ≥ 3 according to National Cancer Institute&#xD;
             Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.5.0&#xD;
&#xD;
          -  Active, second potentially life-threatening cancer&#xD;
&#xD;
          -  Other malignancy within the last 5 years except: adequately treated non-melanoma skin&#xD;
             cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ&#xD;
             (DCIS). Patient with a history of localized malignancy diagnosed over 5 years ago may&#xD;
             be eligible provided he completed her adjuvant systemic therapy and remains free of&#xD;
             recurrent or metastatic disease.&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with&#xD;
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,&#xD;
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               -  Patients with vitiligo or alopecia&#xD;
&#xD;
               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               -  Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               -  Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the study physician&#xD;
&#xD;
          -  Major surgery within 28 days before cycle 1, day 1&#xD;
&#xD;
          -  Active infection requiring iv antibiotics at day 1 of cycle 1&#xD;
&#xD;
          -  Medical condition that requires chronic systemic steroid therapy or on any other form&#xD;
             of immunosuppressive medication. For example, patients with autoimmune disease that&#xD;
             requires systemic steroids or immunosuppression agents should be excluded. Replacement&#xD;
             therapy (eg., thyroxine, or physiologic corticosteroid replacement therapy for adrenal&#xD;
             or pituitary insufficiency, etc.) is not considered a form of systemic treatment.&#xD;
&#xD;
          -  Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs,&#xD;
             resulting in dyspnea at rest&#xD;
&#xD;
          -  Patient is positive for the human immunodeficiency virus (HIV), HepBsAg, or HCV RNA.&#xD;
&#xD;
          -  Live vaccine within 28 days of planned start of study therapy&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation and/or intra-abdominal&#xD;
             abscess within the previous 6 months&#xD;
&#xD;
          -  History of Type I or Type II diabetes mellitus requiring insulin&#xD;
&#xD;
          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins or Chinese Hamster Ovary (CHO)&#xD;
             cell proteins or loperamide drug or excipient&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of atezolizumab, bevacizumab or&#xD;
             ipatasertib&#xD;
&#xD;
          -  Participation in other interventional clinical research that may interfere with the&#xD;
             experimental drugs efficacy&#xD;
&#xD;
          -  History of severe or life-threatening skin adverse reaction on prior treatment with&#xD;
             other immune-stimulatory anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit YOU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Oncologie Médicale - Centre Hospitalier Lyon Sud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoit YOU, MD</last_name>
    <phone>04 78 86 43 18</phone>
    <phone_ext>+33</phone_ext>
    <email>benoit.you@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvie BIN, MD</last_name>
    <phone>04 72 11 53 66</phone>
    <phone_ext>+33</phone_ext>
    <email>sylvie.bin@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dijon - Centre Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François Ghiringhelli, MD</last_name>
      <phone>03 80 73 75 28</phone>
      <phone_ext>+33</phone_ext>
      <email>fghiringhelli@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>François Ghiringhelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hcl - Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien Forestier, MD</last_name>
      <phone>04 72 11 97 38</phone>
      <phone_ext>+33</phone_ext>
      <email>julien.forestier@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Julien Forestier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphm - Hopital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laetitia Dahan, MD</last_name>
      <phone>04 91 38 60 23</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.dahan@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Laetitia Dahan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphp - Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Aparicio, MD</last_name>
      <phone>01 42 49 95 97,</phone>
      <phone_ext>+33</phone_ext>
      <email>thomas.aparicio@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas Aparicio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aphp - Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Baptiste Bachet, MD</last_name>
      <phone>01 42 16 10 41</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-baptiste.bachet@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Baptiste Bachet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux - Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis Smith, MD</last_name>
      <phone>05 56 79 58 08</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Denis Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hcl - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit You, MD</last_name>
      <phone>04 78 86 43 18</phone>
      <phone_ext>+33</phone_ext>
      <email>benoit.you@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit You, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hcl - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marion Chauvenet, MD</last_name>
      <phone>0478861302</phone>
      <phone_ext>+33</phone_ext>
      <email>marion.chauvenet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marion Chauvenet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toulouse - Iuct Rangueil-Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadim Fares, MD</last_name>
      <phone>05 61 32 21 42</phone>
      <phone_ext>+33</phone_ext>
      <email>fares.n@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Nadim Fares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atezolizumab</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Ipatasertib</keyword>
  <keyword>Gastric adenocarcinoma</keyword>
  <keyword>Umbrella phase 2 trial</keyword>
  <keyword>Genomic landscape</keyword>
  <keyword>Personalized Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

